Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	6/17/2003 9:06:05 AM
From: nigel bates	Read Replies (1) of 625

Cambridge Antibody Technology Reports Completion of Enrollment in European Phase II/III Trial of Trabio(TM) in Glaucoma Surgery Tuesday June 17, 9:00 am ET CAMBRIDGE, England, June 17 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (Nasdaq: CATG - News; LSE: CAT - News) today announces the completion of enrollment in its Phase II/III European clinical trial of Trabio(TM), a human monoclonal antibody being developed as an anti-scarring agent to improve the outcome of glaucoma filtration surgery. In this trial, 344 patients undergoing first time trabeculectomy have been enrolled at major eye hospitals in six countries. Data are expected to be available towards the end of 2004. Recruitment continues in the US clinical trial and in the International Phase III clinical trial of Trabio.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next